EpilepsyGTx

EpilepsyGTx is a neurology-focused gene therapy company developing EPY201 for focal refractory epilepsy, and this article provides a weekly summary of notable company updates. Over the past week, EpilepsyGTx highlighted

According to a recent LinkedIn post from EpilepsyGTx, senior leadership contributed to an article in the summer issue of International Clinical Trials on emerging treatments for neurological conditions. The piece

According to a recent LinkedIn post from EpilepsyGTx, the company is collaborating with Viralgen, an AAV-focused contract development and manufacturing organization, to support manufacturing of its lead gene therapy candidate

According to a recent LinkedIn post from EpilepsyGTx, company leadership is drawing attention to emerging modalities for treating drug‑resistant epilepsy, including novel antiseizure medicines, cell and gene therapies, and antisense

According to a recent LinkedIn post from EpilepsyGTx, Professor Dimitri M. Kullmann recently participated in Drug Discovery World’s neuroscience webinar, where he outlined current challenges and opportunities in epilepsy drug

EpilepsyGTx, a gene therapy developer targeting focal refractory epilepsy, reported a constructive week marked by clinical and scientific milestones. The company emphasized its lead program EPY201, which is progressing toward

According to a recent LinkedIn post from EpilepsyGTx, the company’s CSO and scientific founder, Professor Dimitri M. Kullmann, is scheduled to speak at Drug Discovery World’s Neuroscience webinar on 30

EpilepsyGTx is a gene therapy company focused on treating focal refractory epilepsy, and this weekly summary reviews its latest corporate and scientific developments. The company highlighted the appointment of Dr.

According to a recent LinkedIn post from EpilepsyGTx, the company has highlighted the appointment of Dr. Teresa Nunes as Chief Medical Officer. The post indicates that Nunes will lead EPY201,

According to a recent LinkedIn post from EpilepsyGTx, the company’s CSO and scientific founder, Professor Dimitri M. Kullmann, is scheduled to speak at Drug Discovery World’s upcoming neuroscience webinar on